SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

Multiple myeloma (MM)-associated osteolytic bone disease is a major cause of morbidity and mortality in MM patients and the development of new therapeutic strategies is of great interest. The proto-oncogene SRC is an attractive target for such a strategy. In the current study, we investigated the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Heusschen, Roy, Muller, Joséphine, Binsfeld, Marilène, Marty, Caroline, Plougonven, Erwan, Dubois, Sophie, Mahli, Nadia, Moermans, Karen, Carmeliet, Geert, Léonard, Angélique, Baron, Frédéric, Beguin, Yves, Menu, Eline, Cohen-Solal, Martine, Caers, Jo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058712/
https://www.ncbi.nlm.nih.gov/pubmed/27095574
http://dx.doi.org/10.18632/oncotarget.8750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058712/
https://www.ncbi.nlm.nih.gov/pubmed/27095574
http://dx.doi.org/10.18632/oncotarget.8750

Ejemplares similares